Austar Lifesciences (HKSE:06118) Research & Development: HK$50 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06118 Austar Lifesciences Ltd HKSE:06118
45 GF Score
Price HK$0.71
GF Value HK$0.97
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Austar Lifesciences Research & Development?

Austar Lifesciences HKSE:06118 +1.43% 45 Research & Development is HK$50 Mil as of Dec. 2025. GuruFocus rates HKSE:06118 with a GF Score™ of 45/100 and a GF Value™ of HK$0.97 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Austar Lifesciences's Research & Development for the six months ended in Dec. 2025 was HK$32 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$50 Mil.

Austar Lifesciences  (HKSE:06118) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Austar Lifesciences Research & Development Related Terms

Austar Lifesciences Research & Development Historical Data

* Premium members only.

The historical data trend for Austar Lifesciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Austar Lifesciences Research & Development Chart

Austar Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.32 78.35 60.52 57.17 49.79

Austar Lifesciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.48 25.26 32.12 18.01 31.59
HKSE:06118
45GF Score
Austar Lifesciences Ltd HKSE:06118
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Austar Lifesciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$50 Mil mean?
Austar Lifesciences (HKSE:06118) has a Research & Development of HK$50 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Austar Lifesciences and its competitors.
Is Austar Lifesciences' Research & Development too high?
Austar Lifesciences' current Research & Development is HK$50 Mil. Overall, Austar Lifesciences has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' Research & Development compare to ABT and SYK?
Austar Lifesciences' Research & Development of HK$50 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Austar Lifesciences and its competitors. Austar Lifesciences's current Research & Development is HK$50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Austar Lifesciences (HKSE:06118) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.97, compared to a current price of HK$0.71 — trading 26.8% below its estimated fair value. The current Research & Development is HK$50 Mil. Austar Lifesciences' overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Austar Lifesciences (HKSE:06118), the current Research & Development is HK$50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Austar Lifesciences (HKSE:06118) Overvalued in 2026?

Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued. The current stock price of HK$0.71 is trading 26.8% below its estimated GF Value™ of HK$0.97. GuruFocus considers Austar Lifesciences to be Modestly Undervalued.

Key valuation signals for HKSE:06118:

  • Research & Development: HK$50 Mil
  • GF Value™: HK$0.97 vs. price of HK$0.71 (26.8% below fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the HKSE:06118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Austar Lifesciences Business Description

Other Exchanges AULSF:USA
Address No.1018 Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
45GF Score

Get the complete analysis for HKSE:06118

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.71
Price
HK$0.97
GF Value